Ifp Advisors, Inc Immuno Gen, Inc. Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 09, 2024	BUY	$12.46 - $29.95 $6,342 - $15,244	509 Added 158.57%	830 $24,000
Q3 2023 Oct 12, 2023	BUY	$14.09 - $19.87 $3,536 - $4,987	251 Added 358.57%	321 $5,000
Q2 2022 Sep 06, 2022	BUY	$3.15 - $5.76 $220 - $403	70 New	70 $1,000
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $220 - $403	-70 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$6.5 - $10.53 $1,033 - $1,674	-159 Reduced 69.43%	70 $1,000
Q1 2020 May 12, 2020	BUY	$2.12 - $6.8 $148 - $476	70 Added 44.03%	229 $0
Q4 2019 Jan 17, 2020	SELL	$2.25 - $5.8 $123 - $319	-55 Reduced 25.7%	159 $1,000
Q3 2019 Nov 07, 2019	SELL	$2.22 - $3.39 $3,964 - $6,054	-1,786 Reduced 89.3%	214 $0
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $5,444 - $13,350	-2,259 Reduced 53.04%	2,000 $5,000
Q4 2018 Jan 23, 2019	SELL	$3.94 - $9.7 $390 - $960	-99 Reduced 2.27%	4,259 $20,000
Q3 2018 Oct 25, 2018	SELL	$8.6 - $11.26 $868 - $1,137	-101 Reduced 2.27%	4,358 $0
Q2 2018 Aug 07, 2018	SELL	$9.52 - $12.15 $685 - $874	-72 Reduced 1.59%	4,459 $0
Q1 2018 Jun 03, 2019	BUY	$6.7 - $12.95 $482 - $932	72 Added 1.61%	4,531 $29,000
Q1 2018 May 09, 2018	SELL	$6.7 - $12.95 $482 - $932	-72 Reduced 1.59%	4,459 $0
Q4 2017 Jan 24, 2018	BUY	$5.07 - $7.92 $141 - $221	28 Added 0.62%	4,531 $0
Q3 2017 Oct 30, 2017	SELL	$5.4 - $8.47 $5,902 - $9,257	-1,093 Reduced 19.53%	4,503 $34,000
Q2 2017 Jun 03, 2019	SELL	N/A	-200 Reduced 3.45%	5,596 $40,000
Q1 2017 Jun 03, 2019	BUY	N/A	4,152 Added 252.55%	5,796 $22,000
Q4 2016 Jun 03, 2019	BUY	N/A	335 Added 25.59%	1,644 $3,000
Q2 2016 Jun 03, 2019	SELL	N/A	-691 Reduced 34.55%	1,309 $4,000
Q1 2016 Jun 03, 2019	BUY	N/A	2,000	2,000 $5,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account